United States: Uncertainty Remains: FDA Releases New Benefit-Risk Decision Tree For Medical Device PMAs And De Novos In Concert With Final Uncertainty Guidance

Last Updated: September 9 2019
Article by Janice M. Hogan, Randy J. Prebula and Kristin Zielinski Duggan

On 30 August 2019 the U.S. Food and Drug Administration (FDA or the agency) issued a final guidance document entitled "Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions" (uncertainty guidance) in tandem with an updated version of the final guidance "Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications" originally released in August 2016 (benefit-risk guidance).

Taken together, these two guidances seek to provide greater clarity for addressing the acceptable degree of clinical "uncertainty" about a medical device's safety and effectiveness in moving innovative products to market quickly to meet patient needs while also protecting public health from potentially unsafe products. Notably, although the final uncertainty guidance did not differ materially from the draft guidance issued in September 2018, the updated benefit-risk guidance features a completely new worksheet for benefit-risk assessment. The new worksheet follows a decision-tree format (rather than the prior table format) and includes new questions and a sequential method for considering benefit-risk and how to mitigate risks.

Uncertainty guidance

The uncertainty guidance includes illustrative examples of the impact on clinical trial size under different hypothetical scenarios of uncertainty designated "conventional," "modest," and "high," along with recommended shifts to postmarket data collection associated with each level of uncertainty. Although these examples reflect specific statistical thresholds in uncertainty analysis, the guidance stresses that the hypotheticals are not meant to convey established criteria for determinations. It remains to be seen whether this will have any meaningful impact on the threshold level of safety and effectiveness that needs to be established, or whether it will lead to more postapproval study orders because FDA has yet another incentive to ask for them.

In a rare move for FDA, the uncertainty guidance devotes a substantial portion of the document to discussing the purpose for the guidance. This background section emphasizes the "flexible" and "tailored" approach FDA takes in reviewing each device with consideration for the totality of the evidence and the context in which it was generated, such as "the applicable patient population's willingness to accept more uncertainty...particularly when there are no acceptable alternatives available." Thus, while it appears that the agency is seeking a path toward tolerating greater uncertainty in premarket clinical studies, it remains to be seen whether FDA will continue to default to the requirement for randomized, controlled studies in large populations.

FDA is holding a webinar to discuss this new guidance on 16 October 2019.

What's new: benefit-risk guidance

Although the uncertainty guidance in its final form closely tracked the draft, the companion release of the updated final benefit-risk guidance replaces the existing table for benefit-risk assessment with a tool that is completely new in both form and substance.

Sequential methodology

The format of the benefit-risk assessment is substantially changed; what had been a table of factors and mostly high-level questions with space for reviewer notes has become a highly specific checklist in the form of a decision tree. Uncertainty no longer appears as an "additional" factor; it now appears as an integral component throughout the sequencing of questions. Although it is highly prescriptive, the worksheet also leaves considerable room for the discretion of the reviewer.

At a high level, in the new worksheet, FDA reviewers are asked to walk through a checklist of evidence of clinical benefit followed by an assessment of the "degree of uncertainty" as low, medium, or high. A similar process is repeated for assessment of risk, with an assessment of the extent of uncertainty for the risks. Under each, the reviewer is to summarize the assessment of benefits and risks, considering the factors (e.g., type, magnitude of benefit, duration of effects) that appeared in the table in the prior guidance. Reviewers are then asked if the benefits outweigh the risks, taking into account a list of additional considerations (e.g., patient preferences, availability of alternative therapies). Reviewers must then consider whether risks can be mitigated via labeling and training, so that benefits outweigh the risks, and then whether the benefits outweigh the risks considering possible postmarket data collection. If the reviewer is unable to determine whether the benefits outweigh the risks, they are directed to go back to the beginning of the decision tree and review any possible modified indications for use where there is evidence of clinical benefit.

In general, questions prior to the end of the decision tree prompting the reviewer to weigh benefits against risks can be answered with either "yes" or "unable to conclude" (rather than "no"), and also instruct the reviewer to consider all options, so it appears to lean more toward clearance/approval. It also provides a more structured way to consider these options in a particular order (labeling/training first, then postmarket studies, then revised indications).

Assessment of benefits and risks

For assessment of benefit, the flow chart allows for "any evidence of clinical benefit" followed by a checklist with a number of clinical scenarios, which includes the possibility of nonclinical or modeling instead of clinical data. Interestingly, the instructions note that "benefit should be considered based on the assessment of the data, whether or not the results are statistically significant." As such, this decision tree appears to allow more variability in demonstrating evidence of benefit than is typical for FDA, which tends to require both statistical and clinical significance of results. If there is no evidence of clinical benefit, modified indications for use should be considered.

For assessment of risk, the question is framed as "Are known/probable risks more than minimal?" Regardless of whether the answer is "yes" or "no," the decision tree moves on to the next question.

For all the questions in the decision tree, the scenarios are very specific, which is a significant departure from the previous (table) version of the assessment. For example, under the assessment of benefit, options include: "A favorable change in at least 1 clinical assessment that is equal to or greater than seen in the control group"; "A favorable change in at least 1 clinical assessment that meets a predetermined performance goal"; etc. The high degree of specificity in the checklists likely reflects the most common scenarios that FDA typically sees in submissions, but could not cover all scenarios. The checklists provide the option of "Other," presumably to deal with this issue.

How does uncertainty factor into benefit-risk determinations?

Although the decision tree provides highly detailed checklists for uncertainty, it is not clear how the uncertainty analysis figures into the benefit-risk determination. The worksheet requests a determination of whether the extent of uncertainty is "low," "medium," or "high" without defining these categories. It is not clear whether these categories relate to the scenarios in the uncertainty guidance described as "conventional," "modest," or "high" uncertainty. Moreover, the flow chart provides for no divergent path depending on which level of uncertainty is specified. Whether the reviewer checks "low," "medium," or "high," the worksheet simply directs the user to the next question.

Thus, although there is now ample accounting for uncertainty in the new benefit-risk worksheet, there is still significant lack of clarity in how uncertainty factors into the analysis, despite this being the stated purpose of the update to the benefit-risk guidance.

Conclusions

These two guidances provide insight into FDA's approach to determining the appropriate extent of uncertainty for a device in premarket review. Yet considerable uncertainty remains as to how this analysis will be applied. The benefit-risk worksheet is new, containing both new factors and a new, more prescriptive decision-tree format. Given the criticality of the benefit-risk assessment to premarket approval (PMA) and De Novo product reviews, the new worksheet has the potential to impact reviewer decisions on these products. Companies should review the new worksheet carefully and ensure that the factors are addressed in their product submissions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions